Despite progress in the treatment of locally advanced head and neck squamous cell cancer (HNSCC), the prognosis remains dismal and 5-year survival does not exceed 40%. In metastatic and recurrent disease, in spite of the introduction of cetuximab in combination with platinum and fluorouracil, the median overall survival rate remains lower than 11 months. There are many possible reasons for these disappointing results including acquired drug resistance and tumor hypoxia. Angiogenesis plays an important role in HNSCC development and proliferation. Promising preclinical results with antiangiogenic therapies have engendered a number of clinical trials, but so far there have not been any conclusive results on the value of such treatments. This paper aims to review the role of angiogenesis in head and neck cancer and to suggest future perspectives.

Keywords:
Target therapies, Angiogenesis, Head and neck cancer
1.
Brizel DM: Targeting the future in head and neck cancer. Lancet Oncol 2009;10:204–205.
2.
Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182–1186.
3.
Dray TG, Hardin NJ, Sofferman RA: Angiogenesis as a prognostic marker in early head and neck cancer. Ann Otol Rhinol Laryngol 1995;104(9 Pt 1):724–729.
4.
Lentsch EJ, Goudy S, Sosnowski J, Major S, Bumpous JM: Microvessel density in head and neck squamous cell carcinoma primary tumors and its correlation with clinical staging parameters. Laryngoscope 2006;116:397–400.
5.
Kyzas PA, Cunha IW, Ioannidis JP: Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin Cancer Res 2005;11:1434–1440.
6.
Christopoulos A, Ahn SM, Klein JD, Kim S: Biology of vascular endothelial growth factor and its receptors in head and neck cancer: beyond angiogenesis. Head Neck 2011;33:1220–1229.
7.
Williams MD: Integration of biomarkers including molecular targeted therapies in head and neck cancer. Head Neck Pathol 2010;4:62–69.
8.
Geng L, Donnelly E, McMahon G, et al: Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 2001;61:2413–2419.
9.
Li M, Ye C, Feng C, Riedel F, Liu X, Zeng Q, Grandis JR: Enhanced anti-angiogenic therapy of squamous cell carcinoma by combined endostatin and epidermal growth factor receptor-antisense therapy. Clin Cancer Res 2002;8:3570–3578.
10.
Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, Inoue M, Bergers G, Hanahan D, Casanovas O: Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220–231.
11.
Worden B, Yang XP, Lee TL, Bagain L, Yeh NT, Cohen JG, Van Waes C, Chen Z: Hepatocyte growth factor/scatter factor differentially regulates expression of proangiogenic factors through Egr-1 in head and neck squamous cell carcinoma. Cancer Res 2005;65:7071–7080.
12.
Hasina R, Whipple ME, Martin LE, Kuo WP, Ohno-Machado L, Lingen MW: Angiogenic heterogeneity in head and neck squamous cell carcinoma: biological and therapeutic implications. Lab Invest 2008;88:342–353.
13.
Seiwert TY, Cohen EE: Targeting angiogenesis in head and neck cancer. Semin Oncol 2008;35:274–285.
14.
Cao S, Durrani FA, Toth K, Rustum YM, Seshadri M: Bevacizumab enhances the therapeutic efficacy of irinotecan against human head and neck squamous cell carcinoma xenografts. Oral Oncol 2011;47:459–466.
15.
Jain RK, Tong RT, Munn LL: Effect of vascular normalization by anti-angiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res 2007;67:2729–2735.
16.
Jouan-Hureaux V, Boura C, Merlin JL, Faivre B: Modulation of endothelial cell network formation in vitro by molecular signaling of head and neck squamous cell carcinoma (HNSCC) exposed to cetuximab. Microvasc Res 2012;83:131–137.
17.
Schafer JM, Peters DE, Morley T, Liu S, Molinolo AA, Leppla SH, Bugge TH: Efficient targeting of head and neck squamous cell carcinoma by systemic administration of a dual uPA and MMP-activated engineered anthrax toxin. PLoS One 2011;6:e20532.
18.
Yadav A, Kumar B, Teknos TN, Kumar P: Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins. Mol Cancer Ther 2011;10:1241–1251.
19.
Liu J, Kuo WL, Seiwert TY, Lingen M, Ciaccio MF, Jones RB, Rosner MR, Cohen EE: Effect of complementary pathway blockade on efficacy of combination enzastaurin and rapamycin. Head Neck 2011;33:1774–1782.
20.
Dredge K, Hammond E, Handley P, Gonda TJ, Smith MT, Vincent C, Brandt R, Ferro V, Bytheway I: PG545, a dual heparanase and angiogenesis inhibitor, induces potent antitumour and anti-metastatic efficacy in preclinical models. Br J Cancer 2011;104:635–642.
21.
Miyazawa M, Dong Z, Zhang Z, Neiva KG, Cordeiro MM, Oliveira DT, Nör JE: Effect of PTK/ZK on the angiogenic switch in head and neck tumors. J Dent Res 2008;87:1166–1171.
22.
Bozec A, Etienne-Grimaldi MC, Fischel JL, Sudaka A, Toussan N, Formento P, Milano G: The mTOR-targeting drug temsirolimus enhances the growth-inhibiting effects of the cetuximab-bevacizumab-irradiation combination on head and neck cancer xenografts. Oral Oncol 2011;47:340–344.
23.
Bozec A, Sudaka A, Toussan N, Fischel JL, Etienne-Grimaldi MC, Milano G: Combination of sunitinib, cetuximab and irradiation in an orthotopic head and neck cancer model. Ann Oncol 2009;20:1703–1707.
24.
Bozec A, Sudaka A, Fischel JL, Brunstein MC, Etienne-Grimaldi MC, Milano G: Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model. Br J Cancer 2008;99:93–99.
25.
Wang Y, Dong L, Bi Q, Li X, Wu D, Ge X, Zhang X, Fu J, Zhang C, Wang C, Li S: Investigation of the efficacy of a bevacizumab-cetuximab-cisplatin regimen in treating head and neck squamous cell carcinoma in mice. Target Oncol 2010;5:237–243.
26.
Yigitbasi OG, Younes MN, Doan D, et al: Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade. Cancer Res 2004;64:7977–7984.
27.
Xu H, Stabile LP, Gubish CT, Gooding WE, Grandis JR, Siegfried JM: Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells. Clin Cancer Res 2011;17:4425–4438.
28.
Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, Qian F, Chu F, Bentzien F, Cancilla B, Orf J, You A, Laird AD, Engst S, Lee L, Lesch J, Chou YC, Joly A: Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011;10:2298–2308.
29.
Elser C, Siu LL, Winquist E, et al: Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol 2007;25:3766–3773.
30.
Fury MG, Zahalsky A, Wong R, et al: A phase II study of SU5416 in patients with advanced or recurrent head and neck cancers. Invest New Drugs 2007;25:165–172.
31.
Seiwert TY, Haraf DJ, Cohen EEW, Stenson K, Witt ME, Dekker A, Kocherginsky M, Weichselbaum RR, Chen HX, Vokes EE: Phase I study of bevacizumab added to fluorouracil-and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol 2008;26:1732–1741.
32.
Salama JK, Haraf DJ, Stenson KM, Blair EA, Witt ME, Williams R, Kunnavakkam R, Cohen EE, Seiwert T, Vokes EE: A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0–1 head and neck cancers. Ann Oncol 2011;22:2304–2309.
33.
Hainsworth JD, Spigel DR, Greco FA, Shipley DL, Peyton J, Rubin M, Stipanov M, Meluch A: Combined modality treatment with chemotherapy, radiation therapy, bevacizumab, and erlotinib in patients with locally advanced squamous carcinoma of the head and neck: a phase II trial of the Sarah Cannon Oncology Research Consortium. Cancer J 2011;17:267–272.
34.
Harari PM, Khuntia D, Traynor AM, Hoang T, Yang DT, Hartig GK, McCulloch TM, Jeraj R, Nyflot MJ, Wiederholt PA, Gentry LR: Phase I trial of bevacizumab combined with concurrent chemoradiation for squamous cell carcinoma of the head and neck: preliminary outcome results. 47th Annu Meet American Society of Clinical Oncology, 2011.
35.
Vokes EE, Cohen EE, Mauer AM, Karrison TG, Wong SJ, Skoog-Sluman LJ, et al: A phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC). J Clin Oncol 2005;23:5504.
36.
Cohen EE, Davis DW, Karrison TG, Seiwert TY, Wong SJ, Nattam S, Kozloff MF, Clark JI, Yan DH, Liu W, Pierce C, Dancey JE, Stenson K, Blair E, Dekker A, Vokes EE: Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol 2009;10:247–257.
37.
Argiris A, Karamouzis MV, Gooding WE, Branstetter BF, Zhong S, Raez LE, Savvides P, Romkes M: Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. J Clin Oncol 2011;29:1140–1145.
38.
Williamson SK, Moon J, Huang CH, Guaglianone PP, LeBlanc M, Wolf GT, Urba SG: Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420. J Clin Oncol 2010;28:3330–3335.
39.
Fountzilas G, Fragkoulidi A, Kalogera-Fountzila A, et al: A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer. Cancer Chemother Pharmacol 2010;65:649–660.
40.
Choong N, Cohen E, Kozloff M, et al: Phase II trial of sunitinib in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 2008;26:6064.
41.
Meluch A, Spigel D, Burris H, et al: Combined modality therapy with radiation therapy (RT), chemotherapy, bevacizumab, and erlotinib in the treatment of patients (pts) with locally advanced squamous carcinoma of the head and neck. J Clin Oncol 2009;27:6012.
42.
Feinstein T, Raez L, Rajasenan K, et al: Pemetrexed (P) and bevacizumab (B) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC): updated results of a phase II trial. J Clin Oncol 2008;26:6069.
43.
Argiris A, Kotsakis AP, Kim S, Worden FP, Savvides P, Gibson MK, Blumenschein GR, Chen HX, Grandis JR, Kies MS: Phase II trial of cetuximab (C) and bevacizumab (B) in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN): final results. 47th Annu Meet American Society of Clinical Oncology, 2011.
44.
Savvides P, Greskovich J, Bokar J, et al: Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell cancer of the head and neck (SCCHN). Abstracts of the 2007 Multidisciplinary Head and Neck Cancer Symposium 2007:1.
45.
Lee NY, Zhang QE, Garden AS, Kim JJ, Pfister DG, Mechalakos J, Hu K, Le Q, Glisson BS, Chan ATC, Argiris KKA: Phase II study of chemoradiation plus bevacizumab (BV) for locally/regionally advanced nasopharyngeal carcinoma (NPC): preliminary clinical results of RTOG 0615. 47th Annu Meet American Society of Clinical Oncology, 2011.
46.
Fury MG, Lee NY, Sherman E, Lisa D, Kelly K, Lipson B, Carlson D, Stambuk H, Haque S, Shen R, Kraus D, Shah J, Pfister DG: A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer. Cancer 2012, E-pub ahead of print.
47.
Machiels JP, Henry S, Zanetta S, Kaminsky MC, Michoux N, Rommel D, Schmitz S, Bompas E, Dillies AF, Faivre S, Moxhon A, Duprez T, Guigay J: Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01. J Clin Oncol 2010;28:21–28.
48.
Machiels JP, Subramanian S, Ruzsa A, Repassy G, Lifirenko I, Flygare A, Sørensen P, Nielsen T, Lisby S, Clement PM: Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial. Lancet Oncol 2011;12:333–343.
49.
Sano D, Matsumoto F, Valdecanas DR, Zhao M, Molkentine DP, Takahashi Y, Hanna EY, Papadimitrakopoulou V, Heymach J, Milas L, Myers JN: Vandetanib restores head and neck squamous cell carcinoma cells’ sensitivity to cisplatin and radiation in vivo and in vitro. Clin Cancer Res 2011;17:1815–1827.
50.
Donaldson SB, Betts G, Bonington SC, Homer JJ, Slevin NJ, Kershaw LE, Valentine H, West CM, Buckley DL: Perfusion estimated with rapid dynamic contrast-enhanced magnetic resonance imaging correlates inversely with vascular endothelial growth factor expression and pimonidazole staining in head-and-neck cancer: a pilot study. Int J Radiat Oncol Biol Phys 2011;81:1176–1183.
51.
Milano A, Perri F, Ciarmiello A, Caponigro F: Targeted-therapy and imaging response: a new paradigm for clinical evaluation? Rev Recent Clin Trials 2011;6:259–265.
52.
Krajewski KM, Guo M, Van den Abbeele AD, Yap J, Ramaiya N, Jagannathan J, Heng DY, Atkins MB, McDermott DF, Schutz FA, Pedrosa I, Choueiri TK: Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma. Eur Urol 2011;59:856–862.
53.
Lassau N, Koscielny S, Chami L, Chebil M, Benatsou B, Roche A, Ducreux M, Malka D, Boige V: Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification – preliminary results. Radiology 2011;258:291–300.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.